Evidence map›Paper›PMID 33779308›Full record

ArticleAngiology2021

Angiogenin-A Proposed Biomarker for Cardiovascular Disease-Is Not Associated With Long-Term Survival in Patients With Peripheral Artery Disease.

Clemens Höbaus, Gerfried Pesau, Bernhard Zierfuss, Renate Koppensteiner, Gerit-Holger Schernthaner

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Angiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Clemens HöbausDivision of Angiology, Department of Internal Medicine II, 27271Medical University Vienna, Vienna, Austria.ORCID 0000-0002-9704-1452
Gerfried PesauDivision of Angiology, Department of Internal Medicine II, 27271Medical University Vienna, Vienna, Austria.
Bernhard ZierfussDivision of Angiology, Department of Internal Medicine II, 27271Medical University Vienna, Vienna, Austria.
Renate KoppensteinerDivision of Angiology, Department of Internal Medicine II, 27271Medical University Vienna, Vienna, Austria.
Gerit-Holger SchernthanerDivision of Angiology, Department of Internal Medicine II, 27271Medical University Vienna, Vienna, Austria.
Medical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated angiogenin as a prospective biomarker in peripheral artery disease (PAD) patients with and without claudication symptoms. A pilot study suggested an elevation of angiogenin in critical limb ischemia. However, in PAD patients, the predictive value of angiogenin has not yet been evaluated. For this purpose, 342 patients with PAD (age: 69 ± 10 years, 34.5% women) were followed-up for 7 years in a cross-sectional study. Angiogenin was measured by enzyme-linked immunosorbent assay. All-cause and cardiovascular mortality were analyzed by Cox regression. Angiogenin levels were higher in men (

Indexed as

AgedAged, 80 and overBiomarkersCross-Sectional StudiesEnzyme-Linked Immunosorbent AssayFemaleHumansIntermittent ClaudicationMaleMiddle AgedPeripheral Arterial DiseasePilot ProjectsPredictive Value of TestsPrognosisRibonuclease, PancreaticTime FactorsangiogeninBiomarkersRibonuclease, Pancreaticangiogenesisangiogeninmortalityperipheral artery disease

Identifiers

PMID33779308
PMCPMC8436295
OpenAlexW3146481848

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.